Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
Biogen plans to lay off 1000 employees, over 11% of its global workforce, by 2025, as it reorganises to cut costs. The company already shed 900 staff worldwide in 2022, from about 9600 employees to 8700.